The London position statement of the World Congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response

American Journal of Gastroenterology

Volumn 106, Issue 2, 2011, Pages 199-212

  D'Haens, Geert R ^a   Panaccione, Remo ^b   Higgins, Peter D R ^c   Vermeire, Severine ^d   Gassull, Miquel ^e   Chowers, Yehuda ^f   Hanauer, Stephen B ^g   Herfarth, Hans ^h   Hommes, Daan W ⁱ   Kamm, Michael ^j,k   Löfberg, Robert ^l   Quary, A ^m   Sands, Bruce ⁿ   Sood, A ^o   Watermayer, G ^p   Lashner, Bret ^q   Lémann, Marc ^r   Plevy, Scott ^h   Reinisch, Walter ^s   Schreiber, Stefan ^t   Siegel, Corey ^u   Targan, Stephen ^v   Watanabe, M ^w   Feagan, Brian ^x   Sandborn, William J ^y   Colombel, Jean Frédéric ^z   Travis, Simon ^aa   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Germans Trias i Pujol Foundation   (Spain)

^f Rambam Health Care Campus ^*  (Israel)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ST VINCENT S HOSPITAL   (Australia)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l IBD Unit   (Sweden)

^m KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^p UNIVERSITY OF CAPE TOWN   (South Africa)

^q LERNER RESEARCH INSTITUTE   (United States)

^r SAINT LOUIS HOSPITAL   (France)

^s MEDICAL UNIVERSITY OF VIENNA   (Austria)

^t UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^u DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^v CEDARS SINAI MEDICAL CENTER   (United States)

^w TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^x UNIVERSITY OF WESTERN ONTARIO   (Canada)

^y MAYO CLINIC   (United States)

^z LILLE UNIVERSITY HOSPITAL   (France)

^aa JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR;

BIOLOGICAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG CHOICE; HEALTH CARE ORGANIZATION; HUMAN; MONOTHERAPY; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REMISSION; REVIEW; SEPSIS; SURGICAL DRAINAGE; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COLITIS; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79751472562     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.392     Document Type: Review

References (133)

1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
2. Hanauer SB, Feagan BG, Lichtenstein G et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
3. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSICI trial. Gastroenterology 2006; 130: 323-33.
4. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
5. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. New Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
6. Sandborn WJ, Feagan BG, Stoinov S et al. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. New Engl J Med 2007; 357: 228-38. (Pubitemid 47080387)
7. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
8. Colombel JF, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
9. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42. (Pubitemid 43261469)
10. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
11. Schreiber S, Reinisch W, Colombel JF et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: subanalysis of CHARM. Gastroenterology 2007; 132: A-147.
12. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)
13. Hyams J, Crandall W, Kugathasan S et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73. (Pubitemid 46454266)
14. Travis SPL, Stange EF, Lémann M, et al., for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Supplement 1): i16-35. (Pubitemid 43268291)
15. Travis SPL, Stange EF, Lémann M, et al., for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2: 24-62. (Pubitemid 351179488)
16. Lichtenstein G, Cohen R, Feagan B et al. Safety of infliximab and other Crohn's disease therapies: TREAT TM registry data with 24 575 patient-years of follow-up. Am J Gastroenterol 2008; 103: S436.
17. Toruner M, Loft us EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36. (Pubitemid 351451967)
18. Rahier J-F, Ben-Horin S, Eser A, et al., on behalf of the European Crohn's Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009; 3: 47-91.
19. Summers RW, Switz DM, Sessions JT et al. National co-operative Crohn's disease study group: results of drug treatment. Gastroenterology 1979; 77: 847-69. (Pubitemid 9242048)
20. Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. New Engl J Med 1994; 331: 836-41.
21. Rutgeerts P, Lofb erg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5. (Pubitemid 24289711)
22. Benchimol EI, Seow CH, Otley AR et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 1: CD002913.
23. Sandborn WJ, Lofberg R, Feagan B et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100: 1780-7. (Pubitemid 41648434)
24. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60. (Pubitemid 32729372)
25. Munkholm P, Langholz E, Davidsen M et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
26. Ho GT, Chiam P, Drummond H et al. The Efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-30. (Pubitemid 43972900)
27. Modigliani R, Mary JY, Simon JF et al. Clinical biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone Groupe d'Etude Therapeutique des Aff ections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-8. (Pubitemid 20095830)
28. Frøslie KF, Jahnsen J, Moum BA et al. Group I mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
29. Tung J, Loftus EV Jr, Freese DK et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093-100. (Pubitemid 44847465)
30. Bokemeyer B, Katalinic A, Klugmann T et al. Predictive factors for a mild course of Crohn's disease. J Crohn's Colitis 2009; 3: S82.
31. Sutherland LR, Ramcharan S, Bryant H et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-8. (Pubitemid 20143093)
32. Munkholm P, Langholz E, Davidsen M et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23. (Pubitemid 24002788)
33. Langholz E, Munkholm P, Davidsen M et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-51.
34. Jess T, Winther KV, Munkholm P et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002; 122: 1808-14. (Pubitemid 34651425)
35. Duricova D, Pedersen N, Elkjaer M et al. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010; 16: 347-53.
36. Franchimont DP, Louis E, Croes F et al. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998; 10: 821-5. (Pubitemid 28493255)
37. Lichtenstein GR, Olson A, Travers S et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101: 1030-8. (Pubitemid 43725317)
38. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6. (Pubitemid 43374514)
39. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
40. Seksik P, Loftus EV, Beaugerie L et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996. Gastroenterology 2007; 132: A-17.
41. Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-88. (Pubitemid 34977073)
42. Henckaerts L, Van Steen K, Verstreken I et al. Genetic risk profi ling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7: 972-80.
43. Alvarez-Lobos M, Arostegui JI, Sans M et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242: 693-700. (Pubitemid 41567125)
44. Radlmayr M, Torok HP, Martin K et al. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122: 2091-2. (Pubitemid 34651452)
45. Buning C, Genschel J, Buhner S et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19: 1073-8. (Pubitemid 38703519)
46. Ferrante M, Henckaerts L, Joossens M et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-403. (Pubitemid 47517833)
47. Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010; 16: 2609-15.
48. Louis E, Boverie J, Dewit O et al. Belgian IBD Research Group. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 15-9. (Pubitemid 46597996)
49. Colombel JF, Rutgeerts P, Reinisch W et al. SONIC study group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
50. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebocontrolled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
51. Watson K, Dixon WG, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62: 755-63.
52. Lust M, Travis SPL. Is anti-TNF therapy always prohibited in patients with inflammatory bowel disease and previous malignancy? Pract Gastroenterol 2009; 33: 25-30.
53. Lozeron P, Denier C, Lacroix C et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-7.
54. Listing J, Strangfeld A, Kekow J et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-77. (Pubitemid 351364864)
55. Van Assche G, Dignass A, Reinisch W, et al., for the European Crohn's and Colitis Organisation. European evidence-based Consensus on the diagnosis and management of Crohn's disease 2009: special situations. J Crohn's Colitis 2010; 4: 63-101.
56. Thia KT, Mahadevan U, Feagan BG et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
57. Dejaco C, Harrer M, Waldhoer T et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1113-20. (Pubitemid 38021597)
58. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7. (Pubitemid 10125406)
59. West RL, van der Woude CJ, Hansen BE et al. Clinical and endosonographic Effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-36. (Pubitemid 40040080)
60. Van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the Effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332-9. (Pubitemid 36232382)
61. Hyder SA, Travis SPL, Jewell DP et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-41. (Pubitemid 44853440)
62. Tougeron D, Savoye G, Savoye-Collet C et al. Predicting factors of fistula healing and clinical remission aft er infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009; 54: 1746-52.
63. Stange EF, Travis SPL, Vermeire, et al., for the European Crohn's and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of ulcerative colitis: defi nitions and diagnosis. J Crohn's Colitis 2008; 2: 1-23. (Pubitemid 351179487)
64. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison aft er treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
65. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 2005; 128: 1805-11. (Pubitemid 40824691)
66. Cassinnotti A, Travis SPL. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75.
67. Lichtenstein GR, Yan S, Bala M et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99: 91-6. (Pubitemid 38679108)
68. Lichtenstein GR, Bala M, Han C et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-43. (Pubitemid 34784975)
69. Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
70. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25. (Pubitemid 41565956)
71. Colombel JF, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
72. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn's Colitis 2010; 4: S5.
73. Lichtenstein G, Diamond RH, Wagner C et al. Clinical trial: benefi ts and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
74. Hanauer SB, D'Haens GR, Colombel JF et al. Sustained clinical remission in patients with moderate to severe Crohn's disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. Am J Gastroenterol 2006; 101: S457.
75. Lashner B, Feagan BG, Fedorak RF et al. Natalizumab does not require the concomitant use of immunosupressants for the induction of sustained response and remission in Crohn's disease patients. Gastroenterology 2007; 132 (Suppl 2): T1283.
76. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. (Pubitemid 351790744)
77. Lémann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
78. Costes L, Colombel JF, Mary JY et al. Long term follow up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008; 134 (Suppl 1): A-134.
79. Van Assche G, Lewis JD, Lichtenstein G et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: Safety. Am J Gastro enterol 2010 (in press).
80. Feagan B, MacDonald JWD, Panaccione R et al. A randomized, placebocontrolled study to evaluate the Efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease. Gastroenterology 2008; 134 (4 Suppl 1). Abstract 682C.
81. Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-50.
82. Vermeire S, Louis E, Carbonez A et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
83. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing shortterm and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-7. (Pubitemid 36831435)
84. Parsi MA, Achkar JP, Richardson S et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13. (Pubitemid 34977076)
85. FEfferman DS, Lodhavia PJ, Alsahli M et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 2004; 10: 346-51. (Pubitemid 39029176)
86. Topstad DR, Panaccione R, Heine JA et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577-83. (Pubitemid 36576412)
87. Arijs I, Li K, Toedter G et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-9.
88. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 2010; 59: 49-54.
89. Ferrante M, Vermeire S, Katsanos K et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123-8. (Pubitemid 46806219)
90. Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 3: 219-25.
91. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31. (Pubitemid 43268284)
92. Louis E, Vermeire S, Rutgeerts P et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment, but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-24. (Pubitemid 34836819)
93. Schreiber S, Rutgeerts P, Fedorak R et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18. (Pubitemid 41242673)
94. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut 2009; 58: 492-500.
95. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-55. (Pubitemid 32322308)
96. Esters N, Vermeire S, Joossens S et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 1458-62. (Pubitemid 34664792)
97. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the longterm Efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
98. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54. (Pubitemid 44512213)
99. Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity of long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
100. Afif W, Loftus EV, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody levels in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
101. Gustavsson E, Janerot G, Hetevig E. Hospitalized steroid refractory ulcerative colitis treated with infliximab: a 2 year follow-up. Gastroenterology 2007; 132 (Suppl 2): A146-7.
102. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial (GAIN). Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
103. Sandborn WJ, Abreu MT, D'Haens G et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688-95.
104. Allez M, Vermeire S, Mozziconacci N et al. The Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101.
105. Lofberg R, Louis E, Reinisch W et al. Adalimumab Effectiveness in TNFantagonist- naive patients and in infliximab non-responders with Crohn's disease: results from the CARE study. Am J Gastroenterol 2008; 103; 1069.
106. Regueiro M, Siemanowski B, Kip KE et al. Infliximab dose intensifi cation in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9. (Pubitemid 47402592)
107. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13 108. Sandborn WJ, Colombel JF, Rutgeerts P et al. Benefits of dosage adjustment with Adalimumab in Crohn's disease: an analysis of the CHARM trial. Gastroenterology 2008; 134 (Suppl 2): A-347.
108. Sandborn WJ, Schreiber S, Hanauer SB et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: Results from the PRECiSE 4 study. Clin Gastroenterol Hepatol 2010; 8: 696-702.
109. Panaccione R, Sandborn W, Colombel JF et al. Efficacy assessment of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: Results from ENACT-2. Am J Gastroenterol 2004; 99 (Suppl 2): A30.
110. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83. (Pubitemid 46695722)
111. Papadakis KA, Shaye OA, Vasiliauskas EA et al. Safety and Efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75-9. (Pubitemid 41623272)
112. Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to IFX for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-9. (Pubitemid 39421244)
113. Panaccione R, Sandborn WJ, D'Haens G et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after IFX failure: 1-year follow-up of GAIN trial. Gastroenterology 2008; 134 (Suppl 2): A-133.
114. Vermeire S, Abreu MT, D'Haens G et al. Efficacy and safety of Certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to IFX: open-label induction preliminary results of the WELCOME study. Gastroenterology 2008; 134 (Suppl 2): A-67.
115. Louis E, Vernier-Massouille G, Grimaud JC et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136 (Suppl 1): A-146.
116. Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
117. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9. (Pubitemid 29468216)
118. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
119. Sands BE, Blank MA, Patel K et al. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20. (Pubitemid 39335798)
120. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
121. Schreiber S, Colombel JF, Bloomfield R et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105: 1574-82.
122. Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95: 3490-7.
123. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-77.
124. Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-9. (Pubitemid 32240722)
125. Kinney T, Rawlins M, Kozarek R et al. Immunomodulators and on demand therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003; 98: 608-12. (Pubitemid 36348533)
126. Luna-Chadid M, Pérez Calle JL, Mendoza JL et al. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig 2004; 96: 379-81.
127. Laharie D, Salzmann M, Boubekeur H et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005; 29: 145-9. (Pubitemid 40380162)
128. Orlando A, Colombo E, Kohn A et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577-83. (Pubitemid 44356070)
129. Poupardin C, Lémann M, Gendre JP et al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol 2006; 30: 247-52.
130. Pacault V, Ben Hriz F, Gornet J-M et al. Long term follow up of Crohn's disease patients treated with infliximab using an episodic strategy. Gastroenterology 2006; 130 (Suppl 2): A-655.
131. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008; 53: 1033-4.
132. Gonzaga JE, Ananthakrishnan AN, Issa M et al. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis 2009; 15: 1837-43.
133. Cohen RD, Lewis JR, Turner H et al. Predictors and timing of adalimumab (ADA) dose escalation in patients with Crohn's disease. Gastroenterology 2009; 136 (suppl 2): W1093 .